Injection
Tesamorelin
A peptide that targets stubborn abdominal fat and supports a leaner body composition, prescribed and monitored by a licensed clinician.
Starting at $179/mo
Research peptideTissue repair
Pentadeca-Arginate (PDA)
RxPrescription onlyInjected under the skin · 5 days a week · 0.6 mg · Research peptide · Tissue repair
Starting at $209/mo
A research peptide related to BPC-157, studied for tissue repair and healing, used off-label to support recovery from injury.
Choose your plan
Real prices from our pharmacy. Longer plans cost less per month and are billed up front. Pause or cancel anytime.
- Chemically related to BPC-157, the body-protection peptide
- Preclinical evidence for tendon, muscle and wound healing
- Subcutaneous injection, dosed by your physician
Every plan includes
- Personalized, physician-guided plan
- Monthly, 3-month and 6-month plans
- Dispensed by a US-licensed compounding pharmacy
- Unlimited protocol adjustments and messaging
- Ongoing support and check-ins
- Pause or cancel anytime
- Reviewed by our in-house physicians
- Physician-guided care
- Ongoing, expert support
- 100% online
- Free, discreet shipping
What is Pentadeca-Arginate?
(PDA; a BPC-157 analog)
Pentadeca-Arginate is a synthetic peptide designed as a stable analog of BPC-157. Like BPC-157, it is studied for accelerating tissue repair through blood-vessel growth and cell signaling. It is prescribed off-label based on preclinical research and clinical experience.
- How it is taken
- Injected under the skin
- How often
- 5 days a week
- Dose range
- 0.6 mg
- Form
- Research peptide · Tissue repair
Analog
of BPC-157, designed for improved stability
Most evidence is preclinical. Human evidence is very limited. Prescribed off-label at your physician's discretion.
How it works,
week by week.
Day 1
A US-licensed physician reviews your goal, health history and reasons to try this early-stage peptide. You discuss the evidence and the unknowns together.
Week 1
A small subcutaneous injection, usually in the abdomen or near the site you're treating. Most people find the routine comfortable within days.
Week 2–4
Signaling and recovery processes begin. Many report improved energy or easier movement, depending on the peptide.
Month 2+
Your physician checks in, adjusts dose if needed, and follows relevant labs (IGF-1, immune markers, etc.). Tell them everything you notice.
What you may notice,
and when.
Slower feedback
early-stage therapies take time and close monitoring
Individual response
outcomes vary widely because evidence is limited
Physician partnership
your role is to communicate closely at every check-in
Informed choice
you understand the evidence gap before starting
Individual results vary. Benefits reflect what Zepym Health members commonly report to their physician at check-ins; they are not the results of a clinical trial.
Safety first:
what to know before you start.
Important safety information and common side effects
Research peptides are prescribed off-label and carry more uncertainty than established therapies. Common, mild effects include redness, itching or a bump at the injection site, headache, or flushing in the first days. Because these peptides support cell growth or immune signaling, they are not prescribed with an active cancer, a cancer under evaluation, or during pregnancy or breastfeeding. Some (IGF-1) require careful glucose monitoring. Tell your physician about every medication you take, every supplement, and your complete health history, including any autoimmune conditions. Stop and seek care for hives, swelling of the face or lips, or trouble breathing.
The research behind
pentadeca arginate.
Sold as a stabilised salt form of a BPC-157 sequence. We found no published human data on pentadeca arginate itself, and I say so plainly.
- Human datanone published
We found no published human trial of pentadeca arginate and no peer-reviewed study of it as a separate molecule. Its name and sales claims are borrowed from BPC-157.
Narrative review of BPC-157 for musculoskeletal healing, PMC12446177 - BPC-157 basethree pilot studies
The BPC-157 sequence it is based on has been studied in only three small human pilot studies (knee pain, interstitial cystitis, and intravenous safety). Most of the evidence is animal work, and those findings do not transfer automatically to a different salt.
Narrative review of BPC-157 for musculoskeletal healing, PMC12446177 - Regulatory statusnot approved
We found no FDA approval for pentadeca arginate. BPC-157 was nominated for FDA's compounding bulks lists and then appeared among withdrawn nominations; the FDA page, current as of April 22, 2026, still notes possible immunogenicity risks.
FDA, bulk drug substances nominated for compounding
What the studies found
- BPC-157, the sequence it is based on, sped up healing of a transected rat Achilles tendon and of ligaments in animal studies (cited in the review PMC12446177). This is animal work, unproven in people.
- Animal studies of BPC-157 also report better healing of the myotendinous junction, a poorly blood-supplied area. None of this has been tested in people for pentadeca arginate.
- In people, BPC-157 has only three small pilot reports (knee pain, bladder inflammation, intravenous safety), without controls (review PMC12446177). Pentadeca arginate has no human benefit data.
Community timelines for this peptide are not measured outcomes; they are borrowed from BPC-157 practice. Product identity and purity for this salt are not established in public sources.
What this does not say
- We found no human outcome data for pentadeca arginate.
- A different salt can change stability and absorption; the BPC-157 data do not settle it.
- Injection-site reactions and other adverse events are not characterised for this product.
The research
behind it.
Pentadeca arginate is a stabilized salt form of the BPC-157 sequence. The animal studies on tendon and muscle healing were done with BPC-157; pentadeca arginate itself has no published studies yet.
Direct human trials are lacking. Your physician uses it based on its structural relationship to BPC-157 and clinical experience, not approved data.
Getting started
takes a few minutes.
- 1
Connect with a physician
Answer a few questions online and a US-licensed physician reviews your health, history and goals to make sure treatment is right for you. 100% online. No in-person visit required.
- 2
Get your discreet shipment
If approved, your treatment is compounded by a US-licensed, LegitScript-certified pharmacy, inspected for quality, and shipped discreetly to your door.
- 3
Receive continuous support
Start with one goal, then keep building over time. Unlimited physician messaging, easy refills and dose adjustments, all from the Zepym Health app.
Frequently asked questions
Contact supportHow do I use Pentadeca Arginate?
Injected under the skin, 5 days a week. The starting prescription is 20 units (0.6 mg) each time. Your physician sets your own dose and it is printed on your label.
Where do I inject it?
Near the injury site. Change the exact spot each time.
How much arrives in each shipment?
1 vial at the starting strength, shipped to your door from a licensed US pharmacy.
How is PDA different from BPC-157?
It is chemically designed to be a more stable version of BPC-157. Preclinically they show similar effects; human evidence for both is early. Your physician decides whether BPC-157 or PDA fits your situation better.
Why are these off-label?
Off-label means not FDA-approved for these specific uses, but prescribed by physicians based on preclinical evidence and clinical experience. It is common in medical practice; your physician explains the evidence and the gaps.
How often do I take it?
Usually a small subcutaneous injection once daily or a few times a week, depending on the peptide. Your physician sets the schedule and adjusts it as needed. The kit includes everything.
What is the evidence really like?
Honest answer: early. Preclinical and animal data are promising; human data are limited or absent. Your physician explains this plainly and monitors you closely. If you prefer established therapies, tell them.
Pentadeca-Arginate educational content reviewed by our physician
Scott Nass, MD Doctor of Medicine, board-certified in Family Medicine
Charles R. Drew University and David Geffen School of Medicine at UCLA. Family Medicine residency at Ventura County Medical Center.
More options
in this area.
Troche
Sermorelin Troches
The same growth hormone-releasing peptide as a dissolving troche, for people who would rather skip injections.
30 troches per month
Starting at $209/mo
Injection
CJC-1295 / Ipamorelin
Two peptides that prompt your pituitary to release your own growth hormone, used for deeper sleep, recovery and body composition. Prescribed and dosed by a licensed physician.
Starting at $229/mo
Injection
BPC-157
A peptide studied for tissue repair and recovery, used to support healing of muscle, tendon and gut after injury or hard training. Prescribed and dosed by a licensed physician.
Starting at $209/mo
References
- 1.Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells, 2020
- 2.Unique features of human cathelicidin LL-37. Biofactors, 2015
- 3.Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med, 2025
- 4.Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med, 2007
- 5.Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998
- 6.Thymosin alpha 1: A comprehensive review of the literature. World J Virol, 2020
Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate. Products are compounded by a licensed pharmacy. The FDA has not reviewed or approved compounded products for any use for safety, efficacy, or quality. Compounded medications are not FDA-approved brand-name products.